Gemifloxacin (Factive)
Gemifloxacin (Factive - Oscient), a new oral fluoroquinolone antibiotic, has been approved by the FDA for 5 days' treatment of acute bacterial exacerbations of chronic bronchitis (ABECB) and 7 days' treatment of mild to moderate community-acquired pneumonia (CAP) in adults. For the next 6-8 months it will only be available, presumably for commercial reasons, in states east of the Rocky Mountains....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Gemifloxacin (Factive)
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1192
Article Code: 1192b
Date: September 20, 2004
Volume: 46
Pages: 78-79
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1192
Article Code: 1192b
Date: September 20, 2004
Volume: 46
Pages: 78-79
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)